Recently Updated
- 07/01/2011
- Map of Misoprostol Approval
- 06/02/2011
- Map of Mifepristone Approval
- 06/01/2011
- List of Mifepristone Approval
- 06/01/2011
- Misoprostol for Treatment of Postpartum Hemorrhage
- 11/26/2010
- Postpartum Hemorrhage Program Brief
Resources by Type
Activities Brief
Materials Development Activities Brief
Technical Assistance Activities Brief
Training and Education Activities Brief
Policy and Advocacy Activities Brief
Social Science Research Activities Brief
Bibliography/ References
Reference List - Misoprostol for Incomplete Abortion and Miscarriage
Annotated Bibliography - Misoprostol for Early Abortion
Reference List - Misoprostol for Prevention of Postpartum Hemorrhage
Annotated Bibliography - Mifepristone Medical Abortion
Clinical Guidelines
Misoprostol for Early Abortion
Misoprostol for Incomplete Abortion and Miscarriage
Misoprostol for Prevention of Postpartum Hemorrhage
Guidebook on Misoprostol for Treatment of Incomplete Abortion
Abortion With Self-Administered Misoprostol: A Guide For Women
Misoprostol for Treatment of Postpartum Hemorrhage
Fact Sheet
Medical Abortion in the U.S.: Mifepristone Fact Sheet
FAQs on Fatal Infection and Medical Abortion - Summary
Postpartum Hemorrhage: A Challenge for Safe Motherhood
Issue Brief on Hormonal Contraception and HIV
FAQ on Hormonal Contraception and HIV
FAQs on Fatal Infection and Medical Abortion - Technical Version
Map
Meeting Report
Misoprostol and Teratogenicity: Reviewing the Evidence
Route of Misoprostol Administration
Misoprostol: A New Addition to Post Abortion Care
Misoprostol for Women’s Health
Relationship of Hormonal Contraception to HIV
Improving Current Therapies and Exploring New Options in Abortifacient Technology
Misoprostol, Abortion, and the Law
ICMA Third International Conference
The Product Problem: Pathways for Making Misoprostol Available for Postpartum Hemorrhage
Newsletter
Outlook Newsletter on Hormonal Contraception and HIV
PAC in Action Newsletter: Special Issue on Misoprostol in the PAC Context
Policy Brief
Abortion in the Middle East and North Africa
Program Brief
Postpartum Hemorrhage Program Brief
Medical Abortion Program Brief
STIs/ HIV/ Infectious Disease Program Brief
Pregnancy Failure and Miscarriage Program Brief
Project Description
Postpartum hemorrhage: Moving from Research to Reality
Misoprostol for Incomplete Abortion in Guatemala
Research Summary
Blood Loss After Vaginal Delivery
Misoprostol for the Treatment of Postpartum Hemorrhage: Findings from Clinical Research Trials
Fever after treatment of postpartum hemorrhage
Expanding Choice in Abortion Services in Armenia
Misoprostol for the Prevention of Postpartum Hemorrhage: Findings from Research in Pakistan
Staff Publication
Mifepristone medical abortion in Albania
Regimens of misoprostol with mifepristone for early medical abortion
Clostridium sordellii infection in medical abortion
Misoprostol for uterine evacuation in induced abortion and pregnancy failure
Use of sequential serum hCG and sonography for medical abortion only when indicated
Are two doses of misoprostol after mifepristone for early abortion better than one?
Alternatives to mifepristone for early medical abortion
Mifepristone for late first trimester abortion
Can mifepristone medical abortion be simplified?
Methotrexate compared to misoprostol alone for early medical abortion
Assessment of pregnancy duration among termination of pregnancy clients in South Africa
The supreme court and the partial-birth abortion ban act of 2003
Reproductive intentions among HIV-positive women and men
Misoprostol for incomplete abortion in Mozambique
Perspectives on reproductive decision-making amongst HIV-infected individuals
Misoprostol for incomplete abortion in Tanzania
Misoprostol for incomplete abortion in Burkina Faso
Treatment of postpartum hemorrhage with misoprostol
Prevention of postpartum hemorrhage with misoprostol
Treatment of incomplete abortion and miscarriage with misoprostol
Misoprostol to treat missed abortion in the first trimester
Supervision for use of mifepristone medical abortion
Community-based kangaroo mother care to prevent neonatal and infant mortality
Integrating medical abortion into safe abortion services in South Africa
Comment on Misoprostol impairs female reproductive tract innate immunity against C. sordellii
Misoprostol in addition to routine treatment of postpartum hemorrhage in Pakistan
Two distinct oral routes of misoprostol in mifepristone medical abortion
Abortion and sex determination
Sublingual misoprostol after mifepristone
Non-physician clinicians can safely provide first trimester medical abortion
Sublingual misoprostol for incomplete abortion
Oral vs. sublingual misoprostol (400 mcg) following 200 mg mifepristone
Increasing women’s choices in medical abortion in Turkey
Knowledge, attitudes, and practice of abortion among women and doctors in Armenia
Acceptability and feasibility of medical abortion in Nepal
Comparison of serum markers for thrombophilia and autoimmune disease
Sublingual misoprostol for treatment of postpartum hemorrhage Trial 1/2
Sublingual misoprostol for treatment of postpartum hemorrhage Trial 2/2
Alternatives to Routine Follow-Up for Early Medical Abortion
Home administration of misoprostol for early medical abortion in India
High fever following postpartum administration of sublingual misoprostol
What measured blood loss tells us about postpartum bleeding
Misoprostol as adjunct treatment for treatment of postpartum haemorrhage
Unsafe Abortion and Strategies to Reduce its Impact on Women’s Lives
Medical abortion: Outcomes in a family medicine setting
Sublingual misoprostol vs. MVA for the treatment of incomplete abortion in Egypt
Alternatives to routine ultrasound for eligibility assessment prior to medical abortion